Peter G. Rose

Cleveland Clinic — United States

Medicine · Health Sciences

65h-index18.1kcitations442works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ovarian cancer diagnosis and treatment(261), Endometrial and Cervical Cancer Treatments(170), Intraperitoneal and Appendiceal Malignancies(66), Cervical Cancer and HPV Research(52), PARP inhibition in cancer therapy(39)

Publications436 total

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma
Clinical Cancer Research·2025Open Access
Supplementary Data from Disruption of the Gut Microbiota Confers Cisplatin Resistance in Epithelial Ovarian Cancer
2025Open Access
SAFETY OF RUCAPARIB MONOTHERAPY IN ADVANCED HIGH-GRADE OVARIAN CANCER CLINICAL TRIALS
International Journal of Gynecological Cancer·2025
The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series
Gynecologic Oncology Reports·2025· 1 citedOpen Access
Supplementary Table S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Figure S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Table S2 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Data from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Figure S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Table S3 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Supplementary Appendix S1 from Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
2025Open Access
Capability of commercial cleaning procedures to remove food allergens from differing food contact materials and containers using sesame as a target analyte
Journal of Food Engineering·2025· 2 citedOpen Access
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Clinical Cancer Research·2025· 4 citedOpen Access
Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective study
Gynecologic Oncology Reports·2025Open Access
The Use of PARP Inhibitors as Maintenance Therapy in Ovarian Carcinosarcoma: A Case Series
SSRN Electronic Journal·2025Open Access
Temporary Intraperitoneal Breast Implant Spacer to Facilitate Safe Stereotactic Body Radiotherapy for Recurrent High-Grade Serous Ovarian Carcinoma
SSRN Electronic Journal·2025Open Access
A phase II/III study of cediranib and olaparib combination compared to cediranib or olaparib alone or standard of care chemotherapy, in platinum-resistant ovarian cancer (NRG-GY005)
Gynecologic Oncology·2024
GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers
Gynecologic Oncology·2024· 1 cited
Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/RAMP 201 Part A
Gynecologic Oncology·2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Journal of Clinical Oncology·2024· 18 citedOpen Access
page 1 of 22Next →

Frequent Co-authors

John A. Blessing(7), Chunqiao Tian(5), Deborah K. Armstrong(5), Robert S. Mannel(5), Amanda N. Fader(5), Franco M. Muggia(4), William P. McGuire(4), Michael Rodriguez(4), Angeles Alvarez Secord(4), Bradley J. Monk(4), J.T. Thigpen(3), Daniel L. Clarke‐Pearson(3), Maurie Markman(3), Stephen C. Rubin(3), Mark F. Brady(3), Koen DeGeest(3), David M. Gershenson(3), Heidi J. Gray(3), Laura J. Havrilesky(3), David M. O’Malley(3)